Dr Reddy's Laboratories shares fell 7% to a 52-week low of ₹1,101 following a 69% drop in net profit to ₹443 crore for the June quarter. The decline reflects margin pressure from higher operational costs and regulatory delays involving the Semaglutide drug. Investors are closely monitoring the resolution of these regulatory hurdles and the expected ramp-up of new products like Abatacept to gauge future recovery.
Detailed Coverage
Dr Reddy's Laboratories saw its stock price drop to a 52-week low of ₹1,101 on Thursday, reflecting a 7% decline from the previous session. This sharp negative reaction followed the company's financial results for the quarter ending June 30, 2026, which reported a 69% fall in net profit to ₹443 crore.
Margin Pressures and Rising Expenses
The company faced significant hurdles during the quarter that directly impacted its profitability. Higher operational costs, including rising expenses for solvents and freight, weighed heavily on the bottom line. The ongoing conflict in West Asia has added to these logistical challenges by increasing shipping costs. Furthermore, regulatory issues surrounding the company's Semaglutide API (Active Pharmaceutical Ingredient) have created uncertainty, preventing the company from capitalizing on expected growth. Market analysts noted that while revenues were generally in line with expectations, these combined pressures led to margins that were lower than anticipated.
Brokerage Views and Earnings Outlook
Financial institutions have responded to the weak quarterly performance by adjusting their outlooks for the company. Jefferies and Citi have maintained cautious 'underperform' and 'sell' ratings, citing weak performance in the U.S. market and rising costs as primary concerns. Jefferies also highlighted that earnings estimates for the 2027 to 2029 fiscal years have been reduced by up to 15%, partly due to delays in launching Semaglutide in Canada.
Similarly, other analysts have tempered their expectations. While some firms noted that business in India, Russia, and Europe continued to show year-on-year growth, the core profitability remains under pressure from increased administrative and selling expenses. Motilal Oswal expects a period of earnings decline throughout the 2027 fiscal year, with a potential revival only beginning in the 2028 fiscal year as new product cycles begin.
Key Monitorables for Investors
The path to recovery for Dr Reddy's will depend on several specific developments that investors should track in the coming months. A primary focus is the resolution of the regulatory issues related to Semaglutide, which analysts hope to see stabilized by November 2026. Additionally, the successful commercial launch and subsequent ramp-up of Abatacept, expected around the fourth quarter of the 2027 fiscal year, is considered essential for supporting future earnings growth. Investors will also look for signs that freight and raw material costs are stabilizing, as these have been significant drags on the company's profit margins recently.